Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
autologous mononuclear stem cell (1 trial)
bortezomib (velcade) (1 trial)
carfilzomib (kyprolis) (1 trial)
cyclophosphamide (cytoxan) (1 trial)
dexamethasone (1 trial)
ixazomib (ninlaro) (1 trial)
lenalidomide (revlimid) (2 trials)
melphalan (alkeran) (1 trial)
thalidomide (Thalomid) (1 trial)
theostene (1 trial)
urea (1 trial)
vorinostat (zolinza) (1 trial)
chf6001 (1 trial)
roflumilast (daliresp) (1 trial)
Cough (Phase 3)
Frailty (Phase 3)
Multiple Myeloma (Phase 3)
Neoplasms, Plasma Cell (Phase 3)
Trials (4 total)
Trial APIs (14 total)